Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bexarotene Amyloid Treatment for Alzheimer`s Disease


A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer`s Disease




Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer`s disease (AD) and Aß (harmful protein) production and removal. The study drug "bexarotene" is an FDA approved anti-cancer agent but is not approved for use in Alzheimer`s disease. Bexarotene acts as an RXR agonist that has reduced Aß (harmful protein) in the brain in experimental models of Alzheimer`s disease. This study aims to determine the safety and effect on abnormal proteins found in the brain (based on brain scans) of 300 mg of "bexarotene" administered for one month compared to placebo (inactive agent).

Study Status: Active, not recruiting


Condition Intervention Phase
Alzheimer`s Disease Drug: Bexarotene
Drug: Placebo
Phase 2

Verified by The Cleveland Clinic December, 2013

Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic identifier: NCT01782742

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States

Jeffrey L Cummings, MD, ScD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site